ARTICLE | Distillery Therapeutics
Therapeutics: Ribosomal protein S6 kinase 70kDa polypeptide 1 (RPS6KB1; S6K1)
June 23, 2016 7:00 AM UTC
In vitro and mouse studies suggest inhibiting RPS6KB1 could help treat AML and other hematologic malignancies. In a human AML cell line, an RPS6KB1 inhibitor tool compound decreased cell growth compared with vehicle. In a xenograft mouse model of AML, the inhibitor increased survival. Next steps could include testing RPS6KB1 inhibitors in additional models of AML and other hematologic malignancies. ...